<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="81772"><DrugName>TAS-120</DrugName><DrugNamesKey><Name id="43131848">futibatinib</Name></DrugNamesKey><DrugSynonyms><Name><Value>TAS-2985</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>FGFR inhibitors (cancer), Taiho Pharmaceutical Co Ltd</Value></Name><Name><Value>TAS-120</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>irreversible FGFR inhibitor (oral, cancer), Taiho Pharmaceutical/Taiho Oncology</Value></Name><Name><Value>futibatinib</Value><Types><Type>PINN</Type></Types></Name><Name><Value>1448169-71-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18720">Taiho Pharmaceutical Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="18720">Taiho Pharmaceutical Co Ltd</Company><Company id="1092741">Taiho Oncology Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="81772" type="Drug"><TargetEntity id="793703" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="1092741" type="Company"><TargetEntity id="5035254765" type="organizationId">Taiho Oncology Inc</TargetEntity></SourceEntity><SourceEntity id="18720" type="Company"><TargetEntity id="5000071049" type="organizationId">Taiho Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1765" type="ciIndication"><TargetEntity id="D018281" type="MeSH"/><TargetEntity id="70567" type="ORPHANET"/><TargetEntity id="-2122101383" type="omicsDisease"/><TargetEntity id="1844" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="168" type="Action"><TargetEntity id="1105" type="Mechanism">FGFR Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1765">Cholangiocarcinoma</Indication><Indication id="3713">Advanced solid tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="168">FGF receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><LastModificationDate>2019-06-13T11:24:03.000Z</LastModificationDate><ChangeDateLast>2019-06-11T00:00:00.000Z</ChangeDateLast><AddedDate>2012-11-07T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18720" linkType="Company"&gt;Taiho Pharmaceutical&lt;/ulink&gt; and its subsidiary &lt;ulink linkID="1092741" linkType="Company"&gt;Taiho Oncology&lt;/ulink&gt; are developing TAS-120 (presumed to be futibatinib),  an irreversible FGFR inhibitor from a series of small molecule inhibitors of FGFR-1, -2, -3 and -4, for the potential oral treatment of cancer including solid tumors [&lt;ulink linkID="1337807" linkType="Reference"&gt;1337807&lt;/ulink&gt;],  [&lt;ulink linkID="1590382" linkType="Reference"&gt;1590382&lt;/ulink&gt;],  [&lt;ulink linkID="1590947" linkType="Reference"&gt;1590947&lt;/ulink&gt;]. In July 2014, a phase I/II trial in advanced solid tumors, including cholangiocarcinoma, was initiated in the US, Europe and Australia [&lt;ulink linkID="1590947" linkType="Reference"&gt;1590947&lt;/ulink&gt;]; in June 2017, data were presented [&lt;ulink linkID="1953425" linkType="Reference"&gt;1953425&lt;/ulink&gt;]; by February 2018, the trial had been initiated in Taiwan [&lt;ulink linkID="2004115" linkType="Reference"&gt;2004115&lt;/ulink&gt;]; in April 2018, the trial in intrahepatic cholangiocarcinoma was initiated in Japan [&lt;ulink linkID="2119248" linkType="Reference"&gt;2119248&lt;/ulink&gt;]; in May 2018, the study was expected to complete in September 2019 [&lt;ulink linkID="1590947" linkType="Reference"&gt;1590947&lt;/ulink&gt;]. In July 2014, phase I trials were initiated in Japan [&lt;ulink linkID="1611952" linkType="Reference"&gt;1611952&lt;/ulink&gt;]. In June 2018, the phase II trial of TAS-120 in CCA patients was initiated [&lt;ulink linkID="2046751" linkType="Reference"&gt;2046751&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Taiho was previously investigating TAS-2985 from the program of small molecule inhibitors of FGFR-1, -2, -3 and -4  [&lt;ulink linkID="1337807" linkType="Reference"&gt;1337807&lt;/ulink&gt;]; however, by September 2014, Taiho decided to test TAS-120 in clinical trials [&lt;ulink linkID="1590382" linkType="Reference"&gt;1590382&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In May 2018, the FDA granted Orphan designation to futibatinib, for treatment of cholangiocarcinoma [&lt;ulink linkID="2041927" linkType="Reference"&gt;2041927&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In February 2019, the COMP recommended granting futibatinib Orphan designation for treatment of biliary tract cancer [&lt;ulink linkID="2127157" linkType="Reference"&gt;2127157&lt;/ulink&gt;]; in April 2019, the Orphan designation was granted [&lt;ulink linkID="2151157" linkType="Reference"&gt;2151157&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In July 2014, phase I trials were initiated in Japan [&lt;ulink linkID="1611952" linkType="Reference"&gt;1611952&lt;/ulink&gt;]. In September 2017, clinical data from a Japanese first-in-human open-label, non-randomized, dose-escalation phase I study (&lt;ulink linkID="203907" linkType="Protocol"&gt;JapicCTI-142552&lt;/ulink&gt;) which evaluated the efficacy of TAS-120 in patients with advanced solid tumors were presented at the ESMO 2017 Congress in Madrid, Spain. Patients received TAS-120 tiw (on Monday, Wednesday and Friday) for 3 weeks in one cycle in the dose escalation phase in an accelerated titration design, followed by traditional 3 +3 design. Between July 2014 and May 2017, a total of 38 patients were enrolled to eight dose levels. In patients, the most common adverse drug reaction was hyperphosphatemia (n = 31).  At both cycle 1 day 1 and Wednesday in third week treatment period, patients demonstrated a dose-dependent manner of increase in Cmax and AUC (0-48). At doses &amp;gt;/= 56 mg, the mean elimination t1/2 was in the range of 5.11 to 7.66 h [&lt;ulink linkID="1960756" linkType="Reference"&gt;1960756&lt;/ulink&gt;]. In February 2018, the trial was ongoing in Japan in patients with advanced solid tumors. At that time, the trial was expected to complete in  March 2019 [&lt;ulink linkID="2082842" linkType="Reference"&gt;2082842&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2014, an open-label, dose-finding, safety and efficacy phase I/II trial (&lt;ulink linkID="171156" linkType="Protocol"&gt;NCT02052778&lt;/ulink&gt;; TPU-TAS-120-101) was initiated in the US, Europe and Australia in advanced solid tumor patients with or without FGF/FGFR related abnormalities (expected n = 835, Taiwan n = 10). The trial would be followed by a phase II trial in  advanced solid tumor patients or multiple myeloma with FGF/FGFR related abnormalities. At that time, the trial was expected to complete in  December 2018 [&lt;ulink linkID="1590947" linkType="Reference"&gt;1590947&lt;/ulink&gt;]. In June 2017, clinical data of cholangiocarcinoma patients were presented at the 19th World Congress on Gastrointestinal Cancer in Barcelona, Spain. Of eight patients with FGFR2 fusions, partial response was achieved by four (two confirmed, one pending confirmation and one unconfirmed) and tumor shrinkage was observed in additional two patients. Of three patients previously treated with an FGFR inhibitor and with FGFR2 fusions, one achieved a confirmed partial response after 2 cycles and was currently on study (127 days), one had stable disease for 225 days and one was on study for 21 days. Treatment-related adverse events were experienced by seven patients [&lt;ulink linkID="1953425" linkType="Reference"&gt;1953425&lt;/ulink&gt;]. By February 2018, this phase I/II trial had been initiated in Taiwan [&lt;ulink linkID="2004115" linkType="Reference"&gt;2004115&lt;/ulink&gt;]. In April 2018, further data were presented at the 109th AACR Annual Meeting in Chicago, IL. Of nine patients who receiving 24 mg qd, three patients experienced DLTs; and 20 mg QD was identified as MTD as no DLTs were observed among first five patients who received 20 mg, QD. In the QD cohorts, three patients with cholangiocarcinoma achieved a confirmed partial response. Overall, TAS-120 was well tolerated, with manageable toxicities at doses at or below the MTD. At that time, a dose-expansion portion of the study was ongoing [&lt;ulink linkID="2022841" linkType="Reference"&gt;2022841&lt;/ulink&gt;]. Further data were presented at the same conference. In patients with FGFR2-ZMYM4 fusion, FGFR2-SORSBS1 fusion, FGFR2-NRAP rearrangement and FGFR2-INA fusion mutations, the progression-free survival was 7.6, 15.9, 9.0+ and 2.9+ months, respectively [&lt;ulink linkID="2022298" linkType="Reference"&gt;2022298&lt;/ulink&gt;]. In April 2018, the trial in intrahepatic cholangiocarcinoma was initiated in Japan [&lt;ulink linkID="2119248" linkType="Reference"&gt;2119248&lt;/ulink&gt;]. In May 2018, the trial was expected to complete in September 2019 [&lt;ulink linkID="1590947" linkType="Reference"&gt;1590947&lt;/ulink&gt;]. In  June 2018, data from the trial were presented at the  ESMO 20th World Congress on 		Gastrointestinal Cancer 2018 (ESMO-GI) in Barcelona, Spain. Data demonstrated that In the study of 45 patients with CCA harboring FGF/FGFR aberrations, TAS-120 demonstrated clinical activity in patients with CCA with FGFR2 gene fusions, and showed efficacy in patients who progressed on prior FGFR inhibitors. In 28 patients with FGFR2 gene fusions, 71 percent experienced tumor shrinkage and seven achieved confirmed partial response (cPR). The objective response rate in these patients was 25%, and 15 patients (54%) experienced stable disease as their best response, with seven still on treatment. The overall disease control rate was 79%. In 17 patients with other FGF/FGFR aberrations who received TAS-120, 18% achieved cPR. In 13 patients who had received prior FGFR inhibitors, 31 percent achieved cPR.  At that time,  the phase II trial of TAS-120 in CCA patients was initiated [&lt;ulink linkID="2046751" linkType="Reference"&gt;2046751&lt;/ulink&gt;]. Further data were presented at the same conference. Grade 3 adverse events like hyperphosphatemia, constipation, increased AST, increased ALT, diarrhea, nausea, palmar-plantar erythrodysesthesia syndrome and stomatitis were reported were 62.2% of patients.  All these were drug-related except for nausea [&lt;ulink linkID="2054706" linkType="Reference"&gt;2054706&lt;/ulink&gt;]. In April 2019, further results were presented at the 2019 AACR Annual Meeting in Atlanta, GA. The most common on-target mechanism-based adverse effect of TAS-120 was hyperphosphatemia. In patients with BC (both HER2+ and triple-negative), UC, primary CNS tumors and GC, partial responses were observed. Continuous TAS-120 at 20 mg qd was determined to be safe [&lt;ulink linkID="2133857" linkType="Reference"&gt;2133857&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In September 2017, preclinical data were presented at the 76th Annual Meeting of the Japanese Cancer Association in 	Yokohama, Japan. TAS-120 1 showed higher selectivity against FGFRs among several hundreds of kinases and demonstrated a superior antitumor effect on cancers harboring FGFR genetic alterations.TAS-120 was effective against cells with FGFR mutations refractory to ATP competitive FGFR inhibitors [&lt;ulink linkID="1992658" linkType="Reference"&gt;1992658&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2013, preclinical data were presented at the 25th International AACR-NCI-EORTC Symposium in Boston, MA. TAS-120 inhibited mutant FGFR2 resistant to dovitinib, whereas ATP competitive inhibitors showed cross-resistance. TAS-120 was found to be effective and showed lower drug-resistance when compared with ATP competitive inhibitors. [&lt;ulink linkID="1490908" linkType="Reference"&gt;1490908&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2013, preclinical data were presented at the 25th International AACR-NCI-EORTC Symposium in Boston, MA.  In vivo, TAS-120 showed antitumor efficacy in FGFR1 amplified breast cancer xenograft model. TAS-120 (15 and 50 mg/kg) also showed antitumor efficacy in FGFR2 mutated endometrial cancer xenograft models [&lt;ulink linkID="1490905" linkType="Reference"&gt;1490905&lt;/ulink&gt;]. In October 2013, further data were presented at the same conference.  In OCUM-2MD3 human gastric tumor xenograft nude mouse model, intermittent dosing (qd, q2w and every other day) of TAS-120 resulted in durable tumor regression. In SNU-16 nude rat xenograft model, intermittent dosing of TAS-120 showed comparable efficacy in inhibiting the tumor growth when compared with consecutive dosing regimen [&lt;ulink linkID="1490913" linkType="Reference"&gt;1490913&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, data were presented at the 24th EORTC-NCI-AACR symposium in Dublin, Ireland. This compound showed highly potent and irreversible FGFR inhibitory activity with IC50 values in the range of 1.7 to 13 nM. This compound inhibited pFGFR2 in SNU-16, OCUM-2M and Kato III cells with IC50 values of 2.8, 4.2 and 2.5 nM, respectively. The growth of human gastric cancer cells with FGFR2 activation was highly and selectively inhibited by TAS-2985 [&lt;ulink linkID="1336595" linkType="Reference"&gt;1336595&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, data were presented at the 24th EORTC-NCI-AACR symposium in Dublin, Ireland. In mouse xenograft tissues, TAS-2985 inhibited pFGFR2 signaling. In RT112/84 xenograft, TAS-2985 inhibited FGFR3 signaling. In KMS-11 xenograft tumor, po TAS-2985 inhibited FGFR3 phosphorylation and also caused doe-dependent tumor inhibition with minimal body weight reduction. TAS-2985 demonstrated potent tumor growth inhibition in SNU-16 xenograft balb/c nude mouse and F344 nude rat models without body weight reduction. In OCUM-2MD3 xenograft balb/c nude mouse and F344 nude rat models, TAS-2985, demonstrated potent antitumor activity. TAS-2985 demonstrated dose-dependent tumor growth inhibition in RT-112/84 mouse model with minimal loss of body weight [&lt;ulink linkID="1336615" linkType="Reference"&gt;1336615&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1092741">Taiho Oncology Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate>2014-07-25T00:00:00.000Z</StatusDate><Source id="1590947" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1092741">Taiho Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate>2014-07-25T00:00:00.000Z</StatusDate><Source id="1590947" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1092741">Taiho Oncology Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2018-02-05T00:00:00.000Z</StatusDate><Source id="2004115" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1092741">Taiho Oncology Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2014-07-25T00:00:00.000Z</StatusDate><Source id="1590947" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1092741">Taiho Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2014-07-25T00:00:00.000Z</StatusDate><Source id="1590947" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1092741">Taiho Oncology Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate>2014-07-25T00:00:00.000Z</StatusDate><Source id="1590947" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1092741">Taiho Oncology Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2014-07-25T00:00:00.000Z</StatusDate><Source id="1590947" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18720">Taiho Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate>2018-04-30T00:00:00.000Z</StatusDate><Source id="2119248" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18720">Taiho Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2014-07-31T00:00:00.000Z</StatusDate><Source id="1611952" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1092741">Taiho Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2014-06-30T00:00:00.000Z</StatusDate><Source id="1590382" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18720">Taiho Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2012-11-06T00:00:00.000Z</StatusDate><Source id="1337807" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1092741">Taiho Oncology Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2018-02-05T00:00:00.000Z</StatusDate><Source id="2004115" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1092741">Taiho Oncology Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2014-07-25T00:00:00.000Z</StatusDate><Source id="1590947" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1092741">Taiho Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2014-07-25T00:00:00.000Z</StatusDate><Source id="1590947" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1092741">Taiho Oncology Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2014-07-25T00:00:00.000Z</StatusDate><Source id="1590947" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18720">Taiho Pharmaceutical Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="1516">Biliary cancer</Indication><AwardedIndication>Treatment of biliary tract cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2019-04-01T00:00:00.000Z</MileStoneDate><Source id="2151157" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18720">Taiho Pharmaceutical Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="1516">Biliary cancer</Indication><AwardedIndication>Treatment of biliary tract cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2019-02-21T00:00:00.000Z</MileStoneDate><Source id="2127157" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1092741">Taiho Oncology Inc</OwnerCompany><Country id="US">US</Country><Indication id="1765">Cholangiocarcinoma</Indication><AwardedIndication>Treatment of cholangiocarcinoma (CCA)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-05-23T00:00:00.000Z</MileStoneDate><Source id="2041927" type="CORPORATE"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00735"><Name>FGF receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2152190" linkType="reference" linkID="2152190"&gt;2152190&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>COc1cc(cc(c1)OC)C#Cc2c3c(ncnc3n(n2)[C@H]4CCN(C4)C(=O)C=C)N</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="3398986" number="WO-2016159327" title="Crystal of 3,5-disubstituted benzene alkynyl compound"/><PatentFamily id="3779990" number="WO-2017150725" title="Preparation and composition for treatment of malignant tumors"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Otsuka Holdings Co Ltd" id="1040632"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>